Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Simoons, M. L.
PubMed
Right arrow Articles by Simoons, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease

Maarten L. Simoons*

Department of Cardiology, Thoraxcentrum, Erasmus MC, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

* Corresponding author. Tel: +31 10 703 3938, Fax: +31 10 703 5258, E-mail address: m.simoons{at}erasmusmc.nl

Large clinical trials have documented the efficacy of angiotensin-converting enzyme (ACE) inhibitors in a broad spectrum of patients with or at risk of cardiovascular disease. In particular, ACE inhibitors improve myocardial infarction- and stroke-free survival in patients with heart failure, impaired left ventricular function, acute myocardial infarction, stable coronary disease, stroke, hypertension, and diabetes. Part of this benefit is related to blood pressure reduction, but it is likely that other factors specific to ACE inhibitors also play a role. Since there are important pharmacological differences among ACE inhibitors, those with documented efficacy in specific indications should be chosen. In the combined analysis using individual data from 29 463 patients from ADVANCE, EUROPA, and PROGRESS, perindopril-based treatment has been shown to significantly reduce the risk of mortality and major cardiovascular events among patients with various levels of cardiovascular risk. Evidence for cardiovascular protection with perindopril was consistent in subgroups of patients with different clinical characteristics, concomitant medication use, and across all strata of baseline blood pressure.

Key Words: ACE inhibition • Cardiovascular disease • Perindopril


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.